Skip to main content

Truthout - November 10, 2020

The data released on Monday comes from fewer than 100 participants, and Pfizer released few details about how its vaccine trial is structured.

As the United States shatters global records for COVID-19 infections, news on Monday of early trial data suggesting that a potential vaccine for the virus is 90 percent effective provided a brief sense of relief.

However, scientists and pharmaceutical watchdogs cautioned that the preliminary data released by Pfizer, the multinational giant behind the vaccine, is merely a snapshot of a clinical trial and does not show whether the vaccine is safe and would effectively prevent hospitalizations and deaths among the elderly and medically vulnerable.

Pfizer released the preliminary trial data into a highly charged political atmosphere, with the number of new COVID-19 infections surging as the nation contends with the fallout of an election shaped in so many ways by the pandemic

“The release of preliminary and incomplete clinical trial data by press release to the public is bad science,” said Michael Carome, director of Public Citizen’s Health Research Group, in a statement on Monday. ...
Read full report at Truthout